论文部分内容阅读
目的:探究在支气管哮喘患者中予沙美特罗替卡松行相关治疗的临床疗效。方法:选取支气管哮喘共100例患者,按随机数字表法分治疗组、对照组各50例,治疗组予吸入沙美特罗替卡松;对照组予吸入丙酸氟替卡松,对比两组间临床资料差异性。结果:总有效率:治疗组94.0%,对照组86.0%,症状改善治疗组较对照组优,以上数据行统计分析,差异存在统计学意义(P均<0.05)。不良反应治疗组12.0%,对照组14.0,P>0.05,差异无统计学意义。结论:在支气管哮喘患者中予沙美特罗替卡松行相关治疗后疗效确切,在患者肺功能的改善方面亦存在优于单独丙酸氟替卡松、沙美特罗使用,值得临床推广使用。
Objective: To investigate the clinical efficacy of salmeterol and ticagiline in patients with bronchial asthma. Methods: A total of 100 cases of patients with bronchial asthma were selected and randomly divided into treatment group (n = 50) and control group (n = 50). Salmeterol was given to the treatment group. Fluticasone propionate was given to the control group. Clinical data difference. Results: The total effective rate was 94.0% in the treatment group and 86.0% in the control group, and the symptom improvement was better in the treatment group than in the control group. The above data were statistically analyzed with statistical significance (P <0.05). Adverse reactions in treatment group 12.0%, control group 14.0, P> 0.05, the difference was not statistically significant. CONCLUSIONS: The treatment of patients with bronchial asthma is effective in concomitant treatment with saxitrenolide and pirarubicin, and is superior to fluticasone propionate and salmeterol for improvement of lung function in patients with bronchial asthma. Therefore, it is worth to be used clinically.